Prakt. lékáren. 2010; 6(4): 177-180
Pigmentary disorders - treatment of melasma
- Asklepion, Klinika a institut estetické medicíny, Praha
- Dermatovenerologická klinika 3. LF UK FNKV, Praha
The type and amount of melanin synthesized by the melanocytes, and its distribution pattern in the surrounding keratinocytes, determines
the actual color of the skin. Melanin forms through a series of oxidative reactions involving the amino acid tyrosine in the presence
of the enzyme tyrosinase. Impaired metabolism or impaired distribution of melanin result in hyperpigmenation or depigmentation.
Melasma (or chloasma) is a common disorder of cutaneous hyperpigmentation predominantly affecting sun-exposed areas in women.
The pathogenesis of melasma is not fully understood and treatments are frequently disappointing and often associated with side effects.
Several depigmentation and lightening agents including laser treatment are discussed in this paper.
Keywords: melanin, melasma, hyperpigmentation, photoprotection, therapy
Published: October 1, 2010 Show citation
References
- Bienová M, Kučerová R. Hyperpigmentace u žen středního věku. Med. Pro Praxi. 2007; 2: 80-82.
- Wang SQ, Balagula Y, Osterwalder U. Photoprotection: a Review of the Current and Future Technologies. Dermatologic Therapy. 2010; 23(1): 31-47.
Go to original source... 
Go to PubMed... - Ettler K. Účinky UV záření na kůži a fotoprotekce. Med. Pro Praxi 2007; 6: 273-275.
- Verallo-Rowrell VM, Veralo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta derm Venereol 1989; Suppl. 143: 58-61.
- Shoukat P, Kang M, Chung HS, Cho Ch, Hong MCh, Shin MK, Bae H. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res. 2006; 20: 921-934. Go to original source... Go to PubMed...
- Kameyama K, Sakai C, Kondoh S. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 1996; 34: 29-33. Go to original source... Go to PubMed...
- Oakley AM. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone. Austr J Dermatol. 1996; 37: 96-98. Go to original source... Go to PubMed...
- Jimbow K, Iwashina T, Alena F. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma. J Invest Dermat. 1993; 100: 231-238. Go to original source...
- Friedman M, Grosjean OK, Zahnley JC. On activation of metalloenzymes by lysinoalanine, phenylethylenaminoalanine, alkali-treated food proteins, and sulfon amino acids. Adv Exp Med Biol. 1986; 199: 531-560. Go to original source... Go to PubMed...
- Chang TS, Ding HY, lin H. Identifying 6,7,4-trihydroxyisoflavone as a potent tyrosinase inhibitor. Biosci biotechnol Biochem. 2005; 69: 1999-2001. Go to original source... Go to PubMed...
- Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Cutis. 1996; 57(Suppl. 1): 36-45. Go to PubMed...
- Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology. 2002; 205: 249-254. Go to original source... Go to PubMed...
- Alora MBT, Anderson RR. Recent Developments in Cutaneous Lasers. Lasers in Surgery and Medicine. 2000; 26: 108-118. Go to original source... Go to PubMed...
- Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006; 54: S272-281. Go to original source... Go to PubMed...
- Taylor S, Westerhof W, Im S, Lim J. Noninvasive techniques for the evaluation of skin color, J Am Acad Dermatol 2006; 54: S282-290. Go to original source... Go to PubMed...